BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 35876094)

  • 1. Emerging drugs for the treatment of hereditary angioedema due to C1-inhibitor deficiency.
    Zanichelli A; Montinaro V; Triggiani M; Arcoleo F; Visigalli D; Cancian M
    Expert Opin Emerg Drugs; 2022 Jun; 27(2):103-110. PubMed ID: 35876094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The safety of treatments for angioedema with hereditary C1 inhibitor deficiency.
    Zanichelli A; Wu MA; Andreoli A; Mansi M; Cicardi M
    Expert Opin Drug Saf; 2015; 14(11):1725-36. PubMed ID: 26429506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The importance of recognizing and managing a rare form of angioedema: hereditary angioedema due to C1-inhibitor deficiency.
    Jacobs J; Neeno T
    Postgrad Med; 2021 Aug; 133(6):639-650. PubMed ID: 33993830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Hereditary Angioedema.
    Caballero T
    J Investig Allergol Clin Immunol; 2021 Feb; 31(1):1-16. PubMed ID: 33602658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigational drugs in phase I and phase II clinical trials for hereditary angioedema.
    Farkas H; Debreczeni ML; Kőhalmi KV
    Expert Opin Investig Drugs; 2018 Jan; 27(1):87-103. PubMed ID: 29226721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current treatment options for hereditary angioedema due to C1 inhibitor deficiency.
    Wu MA; Zanichelli A; Mansi M; Cicardi M
    Expert Opin Pharmacother; 2016; 17(1):27-40. PubMed ID: 26512744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hereditary and acquired C1-inhibitor-dependent angioedema: from pathophysiology to treatment.
    Zeerleder S; Levi M
    Ann Med; 2016; 48(4):256-67. PubMed ID: 27018196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hereditary angioedema in children and adolescents - A consensus update on therapeutic strategies for German-speaking countries.
    Wahn V; Aberer W; Aygören-Pürsün E; Bork K; Eberl W; Faßhauer M; Krüger R; Magerl M; Martinez-Saguer I; Späth P; Staubach-Renz P; Weber-Chrysochoou C
    Pediatr Allergy Immunol; 2020 Nov; 31(8):974-989. PubMed ID: 32524650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific Targeting of Plasma Kallikrein for Treatment of Hereditary Angioedema: A Revolutionary Decade.
    Busse P; Kaplan A
    J Allergy Clin Immunol Pract; 2022 Mar; 10(3):716-722. PubMed ID: 34838707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of hereditary angioedema in Japan: Focus on icatibant for the treatment of acute attacks.
    Hide M; Horiuchi T; Ohsawa I; Andresen I; Fukunaga A
    Allergol Int; 2021 Jan; 70(1):45-54. PubMed ID: 32919903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic approaches in hereditary angioedema.
    Antoniu SA
    Clin Rev Allergy Immunol; 2011 Aug; 41(1):114-22. PubMed ID: 21279474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of berotralstat for the treatment of hereditary angioedema.
    Farkas H; Balla Z
    Expert Rev Clin Immunol; 2023 Feb; 19(2):145-153. PubMed ID: 36408587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant human C1 esterase inhibitor for the treatment of hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE).
    Sabharwal G; Craig T
    Expert Rev Clin Immunol; 2015 Mar; 11(3):319-27. PubMed ID: 25669442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current and Prospective Targets of Pharmacologic Treatment of Hereditary Angioedema Types 1 and 2.
    Fijen LM; Bork K; Cohn DM
    Clin Rev Allergy Immunol; 2021 Aug; 61(1):66-76. PubMed ID: 33423210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hereditary angioedema therapies in the United States: movement toward an international treatment consensus.
    Riedl M
    Clin Ther; 2012 Mar; 34(3):623-30. PubMed ID: 22386830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factor XII-independent activation of the bradykinin-forming cascade: Implications for the pathogenesis of hereditary angioedema types I and II.
    Joseph K; Tholanikunnel BG; Bygum A; Ghebrehiwet B; Kaplan AP
    J Allergy Clin Immunol; 2013 Aug; 132(2):470-5. PubMed ID: 23672780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathogenic mechanisms of bradykinin mediated diseases: dysregulation of an innate inflammatory pathway.
    Kaplan AP; Joseph K
    Adv Immunol; 2014; 121():41-89. PubMed ID: 24388213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bradykinin-mediated diseases.
    Kaplan AP
    Chem Immunol Allergy; 2014; 100():140-7. PubMed ID: 24925394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term Prophylaxis with Androgens in the management of Hereditary Angioedema (HAE) in emerging countries.
    Guo Y; Zhang H; Lai H; Wang H; Chong-Neto HJ; Valle SOR; Zhu R
    Orphanet J Rare Dis; 2022 Nov; 17(1):399. PubMed ID: 36324138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Decade of Change: Recent Developments in Pharmacotherapy of Hereditary Angioedema (HAE).
    Bork K
    Clin Rev Allergy Immunol; 2016 Oct; 51(2):183-92. PubMed ID: 27207174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.